Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230226 · ClinicalTrials.gov registry record · NA
Acute Study on Muscle Soreness, Damage, and Performance
A NA study, sponsored by Pharmanex.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT04230226: Completed NA study, sponsored by Pharmanex.
NCT04230226 is a NA study that has completed, run by Pharmanex. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230226, a NA study, has completed, sponsored by Pharmanex.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.
Primary Outcome
Change from baseline on performance by measuring countermovement vertical jump height using a jump mat and associated velocity using a linear transducer.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Pre-workout plus and protein recovery plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-01-21 |
| Est. Completion | 2020-09-16 |
| Phase | NA |
What the finished NCT04230226 record still lists
NCT04230226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04230226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04230226 about?
NCT04230226 is a clinical study titled "Acute Study on Muscle Soreness, Damage, and Performance". The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Pa...
What is the current status of trial NCT04230226?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2020-01-21. Estimated completion is 2020-09-16.
What interventions are being tested in trial NCT04230226?
The interventions under investigation include: Placebo (OTHER), Pre-workout plus and protein recovery plus (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04230226?
This trial is sponsored by Pharmanex, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04230226's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI